Pfizer Inc. (NYSE:PFE) is Signet Investment Advisory Group Inc.’s 9th Largest Position

Signet Investment Advisory Group Inc. reduced its holdings in Pfizer Inc. (NYSE:PFE) by 4.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 63,496 shares of the biopharmaceutical company’s stock after selling 3,146 shares during the period. Pfizer comprises about 2.9% of Signet Investment Advisory Group Inc.’s holdings, making the stock its 9th largest holding. Signet Investment Advisory Group Inc.’s holdings in Pfizer were worth $2,750,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in PFE. BKD Wealth Advisors LLC raised its position in shares of Pfizer by 2.5% in the fourth quarter. BKD Wealth Advisors LLC now owns 104,315 shares of the biopharmaceutical company’s stock valued at $4,553,000 after buying an additional 2,561 shares during the last quarter. Brand Asset Management Group Inc. raised its position in shares of Pfizer by 7.7% in the fourth quarter. Brand Asset Management Group Inc. now owns 8,374 shares of the biopharmaceutical company’s stock valued at $366,000 after buying an additional 598 shares during the last quarter. Farmers & Merchants Investments Inc. raised its position in shares of Pfizer by 4.0% in the fourth quarter. Farmers & Merchants Investments Inc. now owns 211,433 shares of the biopharmaceutical company’s stock valued at $9,229,000 after buying an additional 8,126 shares during the last quarter. Payden & Rygel raised its position in shares of Pfizer by 11.5% in the fourth quarter. Payden & Rygel now owns 808,470 shares of the biopharmaceutical company’s stock valued at $35,290,000 after buying an additional 83,500 shares during the last quarter. Finally, Abacus Planning Group Inc. raised its position in shares of Pfizer by 4.9% in the fourth quarter. Abacus Planning Group Inc. now owns 22,916 shares of the biopharmaceutical company’s stock valued at $1,000,000 after buying an additional 1,075 shares during the last quarter. 71.58% of the stock is owned by hedge funds and other institutional investors.

Shares of PFE traded down $0.74 during mid-day trading on Friday, reaching $34.34. The stock had a trading volume of 20,323,181 shares, compared to its average volume of 35,329,740. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.47 and a quick ratio of 1.21. Pfizer Inc. has a 52-week low of $33.97 and a 52-week high of $46.47. The business’s fifty day moving average is $39.60 and its 200 day moving average is $41.43. The firm has a market cap of $192.87 billion, a price-to-earnings ratio of 11.45, a P/E/G ratio of 2.78 and a beta of 0.63.

Pfizer (NYSE:PFE) last announced its earnings results on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.75 by $0.05. The company had revenue of $13.26 billion during the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 23.58% and a return on equity of 28.10%. Pfizer’s revenue was down 1.5% compared to the same quarter last year. During the same quarter last year, the firm posted $0.77 earnings per share. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.8 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, August 2nd will be paid a dividend of $0.36 per share. This represents a $1.44 annualized dividend and a yield of 4.19%. The ex-dividend date is Thursday, August 1st. Pfizer’s dividend payout ratio (DPR) is presently 48.00%.

In other news, EVP Frank A. Damelio sold 153,184 shares of the firm’s stock in a transaction that occurred on Tuesday, July 2nd. The shares were sold at an average price of $44.09, for a total value of $6,753,882.56. Following the completion of the transaction, the executive vice president now owns 489,647 shares of the company’s stock, valued at $21,588,536.23. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Alexander R. Mackenzie sold 30,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 20th. The shares were sold at an average price of $44.00, for a total transaction of $1,320,000.00. Following the completion of the transaction, the insider now directly owns 80,094 shares of the company’s stock, valued at approximately $3,524,136. The disclosure for this sale can be found here. Company insiders own 0.09% of the company’s stock.

PFE has been the subject of a number of recent research reports. Goldman Sachs Group reiterated a “buy” rating and issued a $49.00 target price on shares of Pfizer in a research report on Monday, June 17th. Morgan Stanley cut shares of Pfizer from an “overweight” rating to an “equal weight” rating and reduced their target price for the company from $48.00 to $40.00 in a research report on Tuesday, July 30th. Credit Suisse Group reiterated a “neutral” rating on shares of Pfizer in a research report on Monday, August 12th. JPMorgan Chase & Co. set a $46.00 price objective on shares of Pfizer and gave the company a “neutral” rating in a report on Monday, July 29th. Finally, Bank of America lowered shares of Pfizer from a “buy” rating to a “neutral” rating in a report on Tuesday, July 30th. Fourteen analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $46.67.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Article: What is the Quick Ratio?

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.